Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity
- PMID: 17949550
Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity
Abstract
Objective: To determine the serum levels of galectin-3 (Gal-3) and galectin-3 binding protein (G3BP) and to evaluate the associations between clinical features and these levels in patients with Behçet's disease (BD).
Methods: Fifty patients with BD (mean age 40.6 +/- SEM 1.4 years; 21 males, 29 females; 26 active and 24 inactive patients), 20 patients with rheumatoid arthritis (RA), and 20 patients with systemic lupus erythematosus (SLE) were enrolled. Clinical features of BD patients including BD activity and severity over the previous 4 weeks were reviewed and serum levels of Gal-3 and G3BP were determined using enzyme-linked immunosorbent assays (ELISA).
Results: Serum Gal-3 levels were significantly higher in total BD patients than in healthy controls (mean +/- SEM, 10.68 +/- 0.93 versus 7.59 +/- 0.48 ng/mL; p = 0.0042 by Student's t-test), and active BD patients had significantly higher levels of serum Gal-3 than inactive patients and controls (13.08 +/- 1.53 in active BD, 8.08 +/- 0.71 ng/mL in inactive BD; p = 0.000039 by one way ANOVA). Although mean G3BP serum levels were not different in total BD patients and controls, active BD patients (6806.63 +/- 468.58 ng/mL) had higher G3BP levels than controls (5421.05 +/- 286.02 ng/mL; p = 0.031 by one way ANOVA). Additionally, serum Gal-3 significantly increased in patients with RA (p = 0.019 by t-test) and SLE (p = 0.00069) and G3BP increased in patients with SLE (p = 0.000012), compared to those in healthy controls. When we analyzed for associations with clinical features over the previous 4 weeks, Gal-3 was associated with orogenital ulcers (p = 0.036 by t-test) and time elapsed from symptom onset (p = 0.032, Pearson's coefficient = 0.314). Serum concentrations of Gal-3 (p = 0.013) and G3BP (p = 0.032) were positively correlated with the BD severity score for the previous 4 weeks. Gal-3 levels were significantly correlated with TNF-alpha (p = 0.048, Pearson's coefficient = 0.281) and G3BP levels were correlated with levels of C-reactive protein (p = 0.021, Pearson's coefficient = 0.329) in total BD patients. In multivariate analysis of all cytokines levels, only Gal-3 was significantly related to BD activity or severity for the previous 4 weeks.
Conclusion: These results suggest that serum levels of Gal-3 and G3BP are increased in active BD patients and Gal-3 can be a new biomarker indicating disease activity in BD although their increments are not disease-specific.
Similar articles
-
Serum galectin-3 levels in patients with Behçet's disease: association with disease activity over a long-term follow-up.J Eur Acad Dermatol Venereol. 2011 Oct;25(10):1168-73. doi: 10.1111/j.1468-3083.2010.03941.x. Epub 2011 Jan 9. J Eur Acad Dermatol Venereol. 2011. PMID: 21214630
-
Galectin 3 and its binding protein in rheumatoid arthritis.Arthritis Rheum. 2003 Oct;48(10):2788-95. doi: 10.1002/art.11287. Arthritis Rheum. 2003. PMID: 14558084
-
Serum galectin-3 and galectin-3 binding protein levels in systemic lupus erythematosus and cutaneous lupus erythematosus.Postepy Dermatol Alergol. 2021 Apr;38(2):274-280. doi: 10.5114/ada.2020.92320. Epub 2020 Jan 17. Postepy Dermatol Alergol. 2021. PMID: 34408596 Free PMC article.
-
Clinical Relevance of Galectin-1 and Galectin-3 in Rheumatoid Arthritis Patients: Differential Regulation and Correlation With Disease Activity.Front Immunol. 2019 Jan 9;9:3057. doi: 10.3389/fimmu.2018.03057. eCollection 2018. Front Immunol. 2019. PMID: 30687310 Free PMC article. Review.
-
Serum Galectin-3 Level in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Iran J Allergy Asthma Immunol. 2024 Oct 6;23(5):476-488. doi: 10.18502/ijaai.v23i5.16777. Iran J Allergy Asthma Immunol. 2024. PMID: 39586742
Cited by
-
Outcome measures used in clinical trials for Behçet syndrome: a systematic review.J Rheumatol. 2014 Mar;41(3):599-612. doi: 10.3899/jrheum.131249. Epub 2014 Feb 1. J Rheumatol. 2014. PMID: 24488418 Free PMC article.
-
Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling.Oncotarget. 2015 Aug 14;6(23):19592-604. doi: 10.18632/oncotarget.4285. Oncotarget. 2015. PMID: 26158764 Free PMC article.
-
Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment-Preliminary Data.Biology (Basel). 2022 Jan 7;11(1):88. doi: 10.3390/biology11010088. Biology (Basel). 2022. PMID: 35053087 Free PMC article.
-
Galectins in the Pathogenesis of Rheumatoid Arthritis.J Clin Cell Immunol. 2013 Sep 30;4(5):1000164. doi: 10.4172/2155-9899.1000164. J Clin Cell Immunol. 2013. PMID: 24416634 Free PMC article.
-
Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases.J Clin Lab Anal. 2017 Sep;31(5):e22074. doi: 10.1002/jcla.22074. Epub 2016 Oct 11. J Clin Lab Anal. 2017. PMID: 27726176 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous